The Case for Early Muscarinic Therapy in Schizophrenia

In "The Case for Early Muscarinic Therapy in Schizophrenia," the panel builds the case for introducing this therapy earlier in a patient's course.

Dr. Jackson asks about titration and monitoring experience beyond positive symptoms, with a focus on day-to-day functioning and self-care. Spencer Simon calls the results totally incredible, especially using the medication adjunctively with long-acting injectables: patients with schizophrenia and co-occurring intellectual disability became more conversational and engaged in daily activities within weeks, with less caregiver burden, following a faster escalation to 100 to 125 mg twice daily. Dr. Jackson shares his own preference for using xanomeline-trospium early, even before an injectable, to avoid dopamine-blockade side effects like movement disorders and prolactin elevation while preserving cognition, and asks the panel about using it at first break or right at the outset of treatment, noting the effect sizes are as strong as traditional antipsychotics.

Dr. Alva turns to Dr. Hicks for a caregiver's perspective on early use. Drawing on her own experience, Dr. Hicks says she wishes this option had existed earlier, describing her daughter's unresolved negative symptoms and weight gain, and now, at 36, thriving and about to travel internationally, a moment Dr. Jackson calls exactly what clinicians live for. Dr. Hunter notes many patients and families now request the medication after their own research, especially at first-break presentation, since younger patients face decades of treatment ahead; the panel is no longer willing to wait months or years to titrate toward control, and instead adds on more if symptoms remain unresolved. Dr. Alva agrees, noting that while older agents like olanzapine and risperidone are still considered heavy hitters, phase two effect sizes for xanomeline-trospium chloride rival clozapine, without the drug-interaction concerns that come with combining traditional antipsychotics.

The next episode in this series, "The Schizophrenia Pipeline: Emerging Mechanisms Beyond Dopamine," looks beyond current options to what is coming next in schizophrenia research.